Sign in

KRTX on NASDAQ

Karuna Therapeutics

Biopharmaceutical company based in Boston, founded in 20091

In its 2024 annual report the company says: “We are a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Our pipeline is primarily built on the broad therapeutic potential of our proprietary lead product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues.”4 Its shares trade on NASDAQ under the symbol KRTX.1

Price unavailable

Last updated Oct 21, 2026.

Overview

2009Founded1

Compare with Polomar Health Services, Inc., BioXcel Therapeutics, Inc. or Unicycive Therapeutics, Inc., or pick any stock.

  • TickerKRTX on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersBoston1
  • Websitekarunatx.com
  • Business address99 High Street, 26Th Floor, Boston, Ma 021103
  • Filer categoryLarge accelerated filer3

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Our pipeline is primarily built on the broad therapeutic potential of our proprietary lead product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. We are initially developing KarXT for the treatment of acute psychosis in adults with schizophrenia, as well as for the treatment of psychosis in Alzheimer's disease, or AD.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-75654.0%Operating margin5
-66311.9%Net margin5
-93.9%Revenue growth, 20235
-34.6%Return on equity5
-$388.7MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development100¢$364.1M
  • Income tax0¢$670.0K

Out of $654.0K in revenue.5 The company lost money this year.

Financial statements

Revenue65$654.0K in 2023
0$10.0M$20.0M$30.0M$40.0M2020: $0$020202021: $37.0M$37.0M20212022: $10.6M$10.6M2022−71%2023: $654.0K$654.0K2023−94%
Operating income7865-$494.8M in 2023+3310% since 2018
-$600.0M-$400.0M-$200.0M02018: -$14.5M-$14.5M20182019: -$45.4M-$45.4M2019+213%2020: -$71.8M-$71.8M2020+58%2021: -$143.9M-$143.9M2021+100%2022: -$289.7M-$289.7M2022+101%2023: -$494.8M-$494.8M2023+71%
Net income7865-$433.7M in 2023+2376% since 2018
-$600.0M-$400.0M-$200.0M02018: -$17.5M-$17.5M20182019: -$44.0M-$44.0M2019+151%2020: -$68.6M-$68.6M2020+56%2021: -$143.8M-$143.8M2021+110%2022: -$276.3M-$276.3M2022+92%2023: -$433.7M-$433.7M2023+57%
Fiscal year2017201820192020202120222023
Revenue$06$37.0M5$10.6M5$654.0K5
Research and development$11.5M7$24.5M8$43.4M6$128.2M5$224.2M5$364.1M5
Operating expenses$180.8M5$300.3M5$495.4M5
Operating income-$14.5M7-$45.4M8-$71.8M6-$143.9M5-$289.7M5-$494.8M5
Income before tax-$143.8M5-$274.9M5-$433.0M5
Income tax$07$08$43.0K6$6.0K5$1.4M5$670.0K5
Net income-$17.5M7-$44.0M8-$68.6M6-$143.8M5-$276.3M5-$433.7M5
Earnings per share-$2.596-$4.945-$8.745-$11.735
Earnings per share (diluted)-$2.596-$4.945-$8.745-$11.735
Shares (weighted, basic)29.1M shares531.6M shares537.0M shares5
Shares (weighted, diluted)29.1M shares531.6M shares537.0M shares5

Compare Karuna Therapeutics with another company

Corporate structure

Karuna Therapeutics sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Karuna Therapeutics

  • Karuna Therapeutics Boston

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Karuna Therapeutics reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$8.5M5 Dec 31, 2023$4.9M5 Dec 31, 2022+74.8%
Accumulated depreciation$3.1M5 Dec 31, 2023$1.7M5 Dec 31, 2022+84.9%
Property and equipment, net$5.4M5 Dec 31, 2023$3.2M5 Dec 31, 2022+69.4%
Operating-lease assets (leased space)$15.1M5 Dec 31, 2023$4.7M5 Dec 31, 2022+222.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$185.8M5 Dec 31, 2023$248.3M5 Dec 31, 2022−25.2%

Leadership

Who has led Karuna Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. William Meury2023–2024

President

  1. William Meury2023–2024

Chief financial officer

  1. Troy A. Ignelzi2019–2023
2010201520202025
Board members and other officers (14)

Timeline

  1. Mar 18, 20248-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights28
  2. Mar 14, 20248-K Other events29
  3. Mar 12, 20248-K Shareholder vote30
  4. Mar 1, 20248-K Other events31
  5. Feb 22, 20248-K Results of operations32
  6. Jan 16, 20248-K Executive or director change; Other events33
  7. Dec 22, 20238-K Other events34
  8. Dec 22, 20238-K Entered a material agreement; Executive or director change35
  9. Nov 2, 20238-K Results of operations36
  10. Aug 3, 20238-K Results of operations; Executive or director change37
  11. Jun 21, 20238-K Ended a material agreement; Shareholder vote38
  12. May 4, 20238-K Results of operations39
  13. Jan 5, 2023New chief executive William Meury becomes CEO13
  14. Jun 28, 2019Went public Listed on NASDAQ1
  15. 2009Founded Founded1

Calendar

When it reported results

  1. Feb 22, 2024Reported quarterly or annual results32
  2. Nov 2, 2023Reported quarterly or annual results36
  3. Aug 3, 2023Reported quarterly or annual results37
  4. May 4, 2023Reported quarterly or annual results39
  5. Feb 23, 2023Reported quarterly or annual results40
  6. Nov 3, 2022Reported quarterly or annual results41
  7. Aug 8, 2022Reported quarterly or annual results42
  8. May 5, 2022Reported quarterly or annual results43

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

230 filings to the SEC since October 2021: 4 annual reports, 7 quarterly reports, 30 major events, 120 insider forms, 24 large holders, 45 other. The latest 20:

  1. Mar 28, 202415-12G EDGAR
  2. Mar 18, 20244 EDGAR
  3. Mar 18, 20244 EDGAR
  4. Mar 18, 20244 EDGAR
  5. Mar 18, 20244 EDGAR
  6. Mar 18, 20244 EDGAR
  7. Mar 18, 20244 EDGAR
  8. Mar 18, 20244 EDGAR
  9. Mar 18, 20244 EDGAR
  10. Mar 18, 20244 EDGAR
  11. Mar 18, 20244 EDGAR
  12. Mar 18, 20244 EDGAR
  13. Mar 18, 20244 EDGAR
  14. Mar 18, 20244 EDGAR
  15. Mar 18, 2024S-8 POS EDGAR
  16. Mar 18, 2024S-8 POS EDGAR
  17. Mar 18, 2024S-8 POS EDGAR
  18. Mar 18, 2024S-8 POS EDGAR
  19. Mar 18, 2024S-8 POS EDGAR
  20. Mar 18, 2024POSASR EDGAR

The 230 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

69 open-market trades by officers, directors and large owners since October 2021: 3 buys and 66 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 8, 2024Brannan Stephen K.Chief Medical OfficerSale5,000$318.34$1.6MForm 4
Feb 8, 2024Brannan Stephen K.Chief Medical OfficerSale5,000$316.13$1.6MForm 4
Jan 8, 2024Brannan Stephen K.Chief Medical OfficerSale15,000$316.81$4.8MForm 4
Dec 8, 2023Brannan Stephen K.Chief Medical OfficerSale10,000$202.37$2.0MForm 4
Nov 8, 2023Brannan Stephen K.Chief Medical OfficerSale5,000$177.85$889.3KForm 4
Oct 9, 2023Brannan Stephen K.Chief Medical OfficerSale5,000$173.24$866.2KForm 4
Sep 8, 2023Brannan Stephen K.Chief Medical OfficerSale5,000$184.04$920.2KForm 4
Sep 1, 2023JONAS JEFFREY MDirectorSale13,809$187.93$2.6MForm 4
Aug 22, 2023Ignelzi Troy A.Chief Financial OfficerSale1,500$175.12$262.7KForm 4
Aug 8, 2023Brannan Stephen K.Chief Medical OfficerSale5,000$180.40$902.0KForm 4
Aug 1, 2023JONAS JEFFREY MDirectorSale13,810$195.81$2.7MForm 4
Jul 3, 2023OLSON LAURIE JDirectorSale1,000$215.65$215.7KForm 4
Jul 3, 2023JONAS JEFFREY MDirectorSale13,810$216.42$3.0MForm 4
May 23, 2023Ignelzi Troy A.Chief Financial OfficerSale9,000$223.41$2.0MForm 4
Apr 20, 2023Miller Andrew CraigPresident of R&DSale15,000$200.13$3.0MForm 4
Apr 18, 2023Miller Andrew CraigPresident of R&DSale30,000$200.16$6.0MForm 4
Apr 10, 2023Brannan Stephen K.Chief Medical OfficerSale5,000$176.88$884.4KForm 4
Apr 3, 2023OLSON LAURIE JDirectorSale1,000$181.02$181.0KForm 4
Mar 9, 2023Brannan Stephen K.Chief Medical OfficerSale5,000$189.51$947.5KForm 4
Feb 21, 2023Ignelzi Troy A.Chief Financial OfficerSale6,000$190.01$1.1MForm 4

All 69 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Apr 10, 2023Daniel S. GoldmanDemocratic, HouseSale$1,001 - $15,000Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Karuna Therapeutics is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARKaruna Therapeutics, Inc.2
  • CIK0001771917
  • Employer ID (EIN)27-06059022
  • Filer statusLarge accelerated filer2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address99 High Street, 26Th Floor, Boston, MA 021102
  • Phone857-449-22442
  • Shares outstanding38,199,272 as of Mar 12, 202453
  • Public float$5.9B as of Jun 30, 202353
  • On EDGAR sinceMar 29, 20192
  • Filings460 in all: 4 (235), 8-K (55), 3 (22), 144 (17), SC 13G/A (15), 10-Q (14), SC 13D/A (13), DEFA14A (11)2
    All 40 form types

    SC 13G (8), 424B5 (6), CORRESP (6), 10-K (5), S-8 (5), S-8 POS (5), DEF 14A (4), UPLOAD (4), SC 13D (3), 424B4 (2), DFAN14A (2), DRS (2), DRS/A (2), DRSLTR (2), EFFECT (2), S-1 (2), S-3ASR (2), SEC STAFF LETTER (2), 10-K/A (1), 10-Q/A (1), 15-12G (1), 25-NSE (1), 4/A (1), 5 (1), 8-A12B (1), ARS (1), CERT (1), DEFM14A (1), POSASR (1), PREM14A (1), S-1/A (1), S-1MEF (1)

  • Latest filingsAnnual report (10-K) Feb 22, 2024
    Quarterly report (10-Q) Nov 2, 2023
    Proxy statement (DEF 14A) Apr 27, 2023
    Latest 8-K (8-K) Mar 18, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
  31. 31
    SEC EDGAROther events
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53